1. Volume 116, Issue 5, Pages 1029-1034 (May 1999)
Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial 
Geert D'Haens*, Sander Van Deventer‡, Ruud Van Hogezand §, Douglas Chalmers∥, Christine Kothe‡, Filip Baert*, Tanja Braakman¶, Thomas Schaible¶, Karel Geboes*, Paul Rutgeerts* 
Gastroenterology 
Volume 116, Issue 5, Pages (May 1999)
DOI: /S (99)
Copyright © 1999 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Improvement in CDAI (ΔCDAI) vs. improvement in endoscopic lesions (ΔCDEIS) in all patients. ●, Infliximab; ▴, placebo. r = 0.561; P =
Gastroenterology  , DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Examples of histological changes in ileal biopsy specimens after infliximab therapy (H&E stain; original magnification 125×). (A) Note the disturbed crypt architecture, dense inflammatory infiltrate, and epithelial damage before treatment (histology score, 8). (B) Four weeks after infliximab administration, the inflammatory infiltrate is reduced to normal levels, and the epithelial damage has been restored. Only the crypt architecture remains disturbed (histology score, 2).
Gastroenterology  , DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions

4. Fig. 2
Examples of histological changes in ileal biopsy specimens after infliximab therapy (H&E stain; original magnification 125×). (A) Note the disturbed crypt architecture, dense inflammatory infiltrate, and epithelial damage before treatment (histology score, 8). (B) Four weeks after infliximab administration, the inflammatory infiltrate is reduced to normal levels, and the epithelial damage has been restored. Only the crypt architecture remains disturbed (histology score, 2).
Gastroenterology  , DOI: ( /S (99) )
Copyright © 1999 American Gastroenterological Association Terms and Conditions